KR100575019B1 - Ｌｔｂ 면역보강제를 갖는 백신 - Google Patents

Ｌｔｂ 면역보강제를 갖는 백신 Download PDF

Info

Publication number
KR100575019B1
KR100575019B1 KR1020007005665A KR20007005665A KR100575019B1 KR 100575019 B1 KR100575019 B1 KR 100575019B1 KR 1020007005665 A KR1020007005665 A KR 1020007005665A KR 20007005665 A KR20007005665 A KR 20007005665A KR 100575019 B1 KR100575019 B1 KR 100575019B1
Authority
KR
South Korea
Prior art keywords
subunit
vaccine
immunogen
coli
mucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007005665A
Other languages
English (en)
Korean (ko)
Other versions
KR20010032425A (ko
Inventor
아그스테리베에티엔네
브랜즈루디
데하안롤케
반샤렌부르그구스타프요한마리
페르바이빌렘로날트
빌슈트얀크리스티안
Original Assignee
듀파르 인터내셔널 리서치 비. 브이.
유니베르시테이트 판 그로닌겐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀파르 인터내셔널 리서치 비. 브이., 유니베르시테이트 판 그로닌겐 filed Critical 듀파르 인터내셔널 리서치 비. 브이.
Publication of KR20010032425A publication Critical patent/KR20010032425A/ko
Application granted granted Critical
Publication of KR100575019B1 publication Critical patent/KR100575019B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020007005665A 1997-11-25 1998-11-24 Ｌｔｂ 면역보강제를 갖는 백신 Expired - Fee Related KR100575019B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203671A EP0919243A1 (en) 1997-11-25 1997-11-25 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
EP97203671.9 1997-11-25

Publications (2)

Publication Number Publication Date
KR20010032425A KR20010032425A (ko) 2001-04-16
KR100575019B1 true KR100575019B1 (ko) 2006-05-02

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007005665A Expired - Fee Related KR100575019B1 (ko) 1997-11-25 1998-11-24 Ｌｔｂ 면역보강제를 갖는 백신

Country Status (24)

Country Link
US (1) US6793928B1 (https=)
EP (2) EP0919243A1 (https=)
JP (1) JP4235359B2 (https=)
KR (1) KR100575019B1 (https=)
CN (1) CN1227032C (https=)
AT (1) ATE238809T1 (https=)
AU (1) AU747061C (https=)
BR (1) BR9815413A (https=)
CA (1) CA2311492C (https=)
CZ (1) CZ299770B6 (https=)
DE (1) DE69814177T2 (https=)
DK (1) DK1071456T3 (https=)
ES (1) ES2198089T3 (https=)
HU (1) HU226214B1 (https=)
IL (2) IL135905A0 (https=)
NO (1) NO324690B1 (https=)
NZ (1) NZ504396A (https=)
PL (1) PL190925B1 (https=)
PT (1) PT1071456E (https=)
RU (1) RU2211050C2 (https=)
SK (1) SK284572B6 (https=)
TR (1) TR200001485T2 (https=)
UA (1) UA72199C2 (https=)
WO (1) WO1999026654A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
EA004794B1 (ru) * 1998-05-08 2004-08-26 Юниверсити Оф Бристоль Вакцина
JP4889175B2 (ja) * 1999-10-18 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 感染性因子に対する免疫応答を刺激するための組成物および方法
RU2223783C1 (ru) * 2002-07-05 2004-02-20 Российская медицинская академия последипломного образования Способ профилактики гриппа и острых респираторных заболеваний у часто болеющих детей
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
WO2005079841A2 (en) * 2003-12-09 2005-09-01 Iomai Corporation Gm1 binding deficient exotoxins for use as immunoadjuvants
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
CA2664168A1 (en) * 2006-10-12 2008-04-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
EP2865390B1 (en) * 2012-06-20 2019-08-21 The University of Tokyo Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
WO2015089707A1 (zh) 2013-12-16 2015-06-25 财团法人农业科技研究所 生产不耐热肠毒素b亚单位的质粒、方法及其套组
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
US20210299247A1 (en) * 2017-11-01 2021-09-30 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP7660523B2 (ja) 2019-05-06 2025-04-11 セリバ・バイオロジクス・インコーポレイテッド アルカリリン酸塩に基づいた癌治療
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法
IE20210235A1 (en) 2020-10-20 2023-08-16 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
TWI896302B (zh) * 2024-08-22 2025-09-01 國立清華大學 重組蛋白及其製備方法、包含重組蛋白的疫苗蛋白質佐劑及重組蛋白用於預防呼吸道疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (https=) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
PT92511A (pt) * 1988-12-07 1990-06-29 Univ Leicester Processo de preparacao de um hospedeiro transformado e de proteinas de fusao da subunidade b de toxina labil ao calor
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents

Also Published As

Publication number Publication date
CN1227032C (zh) 2005-11-16
EP1071456A1 (en) 2001-01-31
CZ20001895A3 (cs) 2000-10-11
AU747061C (en) 2005-02-24
EP0919243A1 (en) 1999-06-02
JP4235359B2 (ja) 2009-03-11
KR20010032425A (ko) 2001-04-16
SK284572B6 (sk) 2005-06-02
AU1875099A (en) 1999-06-15
DK1071456T3 (da) 2003-06-02
CA2311492A1 (en) 1999-06-03
CN1280504A (zh) 2001-01-17
CA2311492C (en) 2011-10-18
SK7762000A3 (en) 2000-11-07
ES2198089T3 (es) 2004-01-16
UA72199C2 (en) 2005-02-15
WO1999026654A1 (en) 1999-06-03
DE69814177T2 (de) 2004-04-08
ATE238809T1 (de) 2003-05-15
HU226214B1 (en) 2008-06-30
PL340635A1 (en) 2001-02-12
IL135905A0 (en) 2001-05-20
BR9815413A (pt) 2000-10-17
PT1071456E (pt) 2003-09-30
PL190925B1 (pl) 2006-02-28
HUP0100058A3 (en) 2003-03-28
CZ299770B6 (cs) 2008-11-19
NO20002613L (no) 2000-05-22
JP2001523729A (ja) 2001-11-27
NZ504396A (en) 2002-09-27
RU2211050C2 (ru) 2003-08-27
HUP0100058A1 (hu) 2001-05-28
NO20002613D0 (no) 2000-05-22
NO324690B1 (no) 2007-12-03
US6793928B1 (en) 2004-09-21
IL135905A (en) 2006-08-01
HK1031102A1 (en) 2001-06-01
EP1071456B1 (en) 2003-05-02
AU747061B2 (en) 2002-05-09
DE69814177D1 (de) 2003-06-05
TR200001485T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
KR100575019B1 (ko) Ｌｔｂ 면역보강제를 갖는 백신
AU770923B2 (en) Inactivated influenza virus vaccine for nasal or oral administration
Sui et al. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant
US8182821B2 (en) Flu vaccine admixture of mannan and flu antigen
Tamura et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine
NO323555B1 (no) Influensavaksine, farmasoytisk utstyr og anvendelse av kitosan.
de Haan et al. Mutational analysis of the role of ADP‐ribosylation activity and GM1‐binding activity in the adjuvant properties of the Escherichia coli heat‐labile enterotoxin towards intranasally administered keyhole limpet hemocyanin
Tamura et al. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit
Komase et al. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine
JP5913406B2 (ja) 変異型大腸菌易熱性エンテロトキシン
WO2008037033A1 (en) Flu vaccine admixture of mannan and flu antigen
AU778957B2 (en) Bacterial membrane fractions with adjuvant effect
HK1031102B (en) Vaccines with an ltb adjuvant
MXPA00005127A (en) Vaccines with an ltb adjuvant
HK1190638B (en) Compositions for canine respiratory disease complex

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20120329

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130425

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130425